Skip to content

A trial to evaluate the efficacy of amylenum nitrosum in management of symptoms in perimenopausal women

A randomized single blind placebo controlled trial to evaluate the efficacy of amylenum nitrosum in management of symptoms in perimenopausal women - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/08/092434
Enrollment
80
Registered
2025-08-05
Start date
Unknown
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N958- Other specified menopausal and perimenopausal disorders

Interventions

Intervention1: Homoeopathic medicene AMYLENUM NITROSUM: 30 in centesimal scale, 4 pills, 1 dose once in a day empty stomach in morning dissolved in one 1/4 tea cup of water for 3 months. Route of admi

Sponsors

Swasthya Kalyan Homoeopathic Medical College and research Center
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Women aged 40-55 year of age. 2. Women with any symptoms stated in Menopause Rating Scale, having LMP less than 1 year and Not attained menopause yet were enrolled in study. 3. No ongoing Hormone Replacement Therapy or major psychiatric illness Cases. 4. Patient who has given written consent. 5. Those who are willing to stop other modes of treatment prior to the registration.

Exclusion criteria

Exclusion criteria: 1. Patients suffering from any systemic illness (for example - Cancer, Autoimmune diseases, Hyperthyroidism/Hypothyroidism,Renal disease, Liver disease) or any advance pathology. 2. Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
The outcome assessment was conducted over a 3month follow up period, with evaluations every 15 days. Menopause Rating Scale scores were recorded at the baseline (first visit) and at the end of the treatment (last visit). The percentage change in symptom scores was calculated using the formula: Percentage = (Score at Baseline Score at End) 100 / Score at Baseline. Based on the percentage improvement, responses were categorized as follows: 0% indicated no improvement (status quo), 26 50% was considered mild improvement, 51 75% moderate improvement, and 76 100% signified significant improvementTimepoint: 12 months

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactDr Yogeshwari gupta

Swasthya kalyan homoeopathic medical college and research centre

homeopathy@swasthyakalyan.org9414229555

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026